SUSMED,Inc.
Stock Price Chart
2026/08/07 UpdatedPrice Trend
2026/08/07 UpdatedPrice & Trading Details
2026/08/07 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/07/01Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Income Statement | |||
| Revenue | ¥317M | ¥531M | ¥343M |
| Gross Profit | ¥306M | ¥523M | ¥331M |
| Operating Income | -¥229M | -¥48M | -¥365M |
| Pretax Income | -¥229M | -¥48M | -¥365M |
| Net Income | -¥233M | -¥51M | -¥357M |
| EPS | -¥15.90 | -¥3.09 | -¥21.41 |
| Operating Margin | -72.32% | -9.10% | -106.54% |
| Balance Sheet | |||
| Total Assets | ¥4,944M | ¥5,101M | ¥4,932M |
| Total Equity | ¥4,850M | ¥4,871M | ¥4,604M |
| Total Liabilities | ¥93M | ¥230M | ¥328M |
| Cash | ¥4,904M | ¥5,049M | ¥4,847M |
| Interest-bearing Debt | - | - | - |
| Equity Ratio | 98.11% | 95.48% | 93.35% |
| D/E Ratio | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||
| Operating CF | -¥165M | ¥101M | -¥231M |
| Investing CF | -¥20M | -¥18M | -¥9M |
| Financing CF | ¥3,463M | ¥62M | ¥37M |
| Free CF | -¥178M | ¥82M | -¥240M |
| Efficiency | |||
| ROE | -4.81% | -1.04% | -7.76% |
| ROA | -4.72% | -0.99% | -7.25% |
Latest IR Information
-
Sasmex Co., Ltd. 2026 Interim June期 Financial Summary
The earnings for the June 2026 term show that revenue and profit figures are described in the text, with indications of YoY comparison. It includes segment information and detailed financial indicators.
Read more -
Notice of Stock Option Treasury Stock Acquisition ｜ July 22, 2026
The company will grant 1,330 stock options free of charge to employees, aiming for long- to medium-term growth and enhanced corporate value. The allocation date is August 7, 2026, with an exercise period from July 23, 2028, to July 21,...
Read more -
Notice of Achievement of Milestone Related to the Joint Research, Development, and Sales Agreement with Kyron Pharmaceutical Co., Ltd.
Read more -
Susmed Achieves Milestone in Sales Partnership | June 2026
Susmed has achieved a milestone in its sales partnership with Shionogi & Co., Ltd., and started sales of the sleep disorder app from June 1. Detailed revenue and figures are yet to be finalized.
Read more
Latest News (5 items)
Company Information
About
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
